LOS ANGELES—HemaCare Corporation (OTCBB:HEMA) a leader in cell and tissue collection, processing and cell therapy solutions, announced that it has expanded its offering of stem cell rich peripheral blood through the addition of a new protocol.
This type of blood, referred to among researchers as “mobilized peripheral blood,” is collected following a procedure that induces the bone marrow to produce more white cells into the periphery. These white cells can then be collected with a routine leukapheresis and provided to researchers within 24 hours.
The most widely studied cell populations within these collections are CD34+ stem cells. These cells are used by investigators to study the mechanism of, and develop therapies for, diseases such as cancer, inflammatory conditions like arthritis and immune deficiency-based pathologies such as HIV. Additionally, this type of premium research material is a critical component to advancing research from the bench into potential clinical trials.
“We decided to expand our mobilized peripheral blood offering in response to our customers who need this specialized collection of cells to obtain the best results from their research in the regenerative medicine communities around the world. We will continue to actively respond to their needs as we participate in their progress toward treatments and ultimately cures,” said Pete van der Wal, HemaCare’s Chief Executive Officer. “We value our ability to exceed our customers’ expectations by supplying human stem cells with consistently high purity, viability, and functionality. Our expertise in GMP-compliant cell collection, handling and logistics has made HemaCare a valuable partner, assisting cell therapy developers with their research, process development, clinical trials, and commercialization needs.” This product line can be viewed at hemacare.com/mobilizedperipheralblood.
Since 1978, HemaCare Bioresearch Products & Services has been the trusted research partner of choice from concept to commercialization. Built on a 38-year history in apheresis collection, HemaCare is a leader in Cell and Tissue Collection, Processing and Cell Therapy, providing the high-quality biological material needed to ensure quality research outcomes that meet the unique needs of the scientific community. For more information please visit www.hemacare.com.
Chris Brotski, 818-251-5335
BioInformant is the first and only market research firm to specialize exclusively in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Medical Ethics, Vogue Magazine, and more. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.